eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This pilot randomized controlled trial seeks: (1) to determine the preliminary efficacy of
our modernized collaborative care intervention for depression in improving the diabetes risk
markers of hemoglobin A1c and insulin resistance and (2) to explore whether somatic
depressive symptoms - i.e., hyperphagia (increased appetite/weight) and/or hypersomnia
(increased sleep) - moderate the effect of the eIMPACT-DM intervention on diabetes risk
markers.
Phase:
Phase 2
Details
Lead Sponsor:
Indiana University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)